CST3 and cardiovascular disorder: Multiple clinical and biochemical factors and inflammatory cytokines have been proved to associate with the severity of CAD, such as C1q/TNF-related protein-1,[12] neutrophil-to-lymphocyte ratio and platelets,[13] serum glycated albumin levels,[14] and plasma chemokine.[15] Cystatin C also has been considered an emerging biomarker in cardiovascular disease (CVD) and proved to be an important predictor for adverse outcomes among patients with CAD.[16,17] However, to date, limited research shows the correlation between cystatin C, GS, and coronary artery lesions.